Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

316 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AVANTOR, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
AVANTOR, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Transcript : AbbVie Inc., Q1 2022 Earnings Call, Apr 29, 2022
ABBVIE INC. : Change in Directors or Principal Officers (form 8-K)
AQ
AbbVie Inc. Announces Resignation of Michael E Severino as Vice Chairman and President
CI
Abbvie Vice Chairman Severino Departs for Flagship Pioneering
DJ
AAON : Annual Report (Form ARS)
PU
Transcript : AbbVie Inc. Presents at 42nd Annual Cowen Health Care Conference, Mar-08-2022 12:50 PM
Transcript : Inventiva S.A., Q4 2021 Earnings Call, Mar 08, 2022
AbbVie to Present at the Cowen 42nd Annual Health Care Conference
PR
AbbVie - Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
AQ
Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ®) Improved Clinical and Endoscopic Outcomes in Patients with Crohn's Disease
PR
Transcript : AbbVie Inc., Q4 2021 Earnings Call, Feb 02, 2022
Transcript : AbbVie Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-11-2022 03:45 PM
AbbVie to Present at the 40th Annual J.P. Morgan Healthcare Conference
PR
AbbVie - Upadacitinib Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease
AQ
Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease
PR
AbbVie Provides Update on RINVOQ for the Treatment of Rheumatoid Arthritis in the U.S.
AQ
AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.
PR
Transcript : AbbVie Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-02-2021 12:10 PM
Transcript : AbbVie Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Dec-01-2021 10:30 AM
AbbVie to Present at the Evercore ISI Conference
PR
AbbVie to Present at the Piper Sandler Healthcare Conference
PR
AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of SKYRIZI (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis
AQ
Transcript : AbbVie Inc. Presents at 3rd Annual Wolfe Research Virtual Healthcare Conference 2021, Nov-17-2021 09:30 AM
AbbVie to Present at the Wolfe Research Healthcare Conference
PR
U.S. Food and Drug Administration Approves VUITY (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)
AQ
AbbVie's Cariprazine (VRAYLAR) Met Primary Endpoint in Phase 3 Study as an Adjunctive Treatment for Major Depressive Disorder
AQ
U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only Eye Drop to Treat Presbyopia (Age-Related Blurry Near Vision)
PR
Transcript : AbbVie Inc., Q3 2021 Earnings Call, Oct 29, 2021
AbbVie Announces ABBV-951 (Foslevodopa/Foscarbidopa) Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial in Patients with Advanced Parkinson's Disease
PR
AbbVie :'s Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis
PR
AbbVie :'s RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondylitis
PR
AbbVie Sees Positive Results in Rinvoq Studies
DJ
AbbVie : FDA Approves QULIPTA (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
AQ
AbbVie : FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine
PR
AbbVie Says FDA Approves Qulipta as Migraine Treatment
DJ
Transcript : Inventiva S.A., H1 2021 Earnings Call, Sep 21, 2021
Transcript : AbbVie Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-15-2021 10:15 AM
AbbVie : to Present at the Morgan Stanley Healthcare Conference
PR
Production Begins on Alejandro Monteverde's 'The Untitled Cabrini Film'
BU
AbbVie : European Commission Approves RINVOQ® (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
PR
Transcript : AbbVie Inc., Q2 2021 Earnings Call, Jul 30, 2021
AbbVie : Provides Update Regarding RINVOQ (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
AQ
AbbVie : Provides Update Regarding RINVOQ® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the U.S.
PR
AbbVie Says FDA Didn't Meet Action Date for Dermatitis Treatment Application
DJ
AbbVie : Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
PR
AbbVie : Provides Update Regarding RINVOQ® (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.
PR
AbbVie Says FDA Won't Meet Action Dates for Arthritis Drug Rinvoq
DJ
AbbVie : CHMP Recommends Approval of RINVOQ® (upadacitinib) for the Treatment of Atopic Dermatitis
PR
No results for this search
  1. Stock Market
  2. Advanced search
  3. Michael Severino
  4. News